SciSparc Ltd

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2023

SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and explor ing the possibility of dividend distributi on

SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

SciSparc (NASDAQ: SPRC ) stock is taking off on Wednesday after the company released results from a Phase IIa trial of SCI-110 as an Alzheimer's Disease agitation treatment. The clinical trial covered 18 patients with Alzheimer's who have been dealing with agitation symptoms.

Why Is SciSparc (SPRC) Stock Up 47% Today?

Phase IIa trial outcome indicates the potential for a new way to help Alzheimer's patients' agitation Tel-Aviv, Nov. 15, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), unveiled positive topline results from its investigator-initiated Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center (IMCA).

SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation

SciSparc to conduct trial at Yale University in the USA, Tel Aviv Sourasky Medical Center in Israel and the Hannover Medical School in Germany

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

SciSparc (NASDAQ: SPRC ) stock is taking off on Tuesday after the pharmaceutical company posted positive patent news. The big news here is the company's patent for ‘Combination of Opioids and N-Acylethanolamines for pain treatment” getting approval from IP Australia.

Why Is SciSparc (SPRC) Stock Up 58% Today?

TEL AVIV, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received notice of acceptance for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment (the “Patent”).

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

The Company's most recent patent further solidifies its position within the cannabis sector, complementing existing grants in the U.S., Europe, and other key jurisdictions

SciSparc Granted Patent for its Core Technology From the Australian Patent Office

SciSparc (NASDAQ: SPRC ) stock is rising higher on Tuesday after the pharmaceutical company regained listing compliance. SciSparc notes that the Nasdaq Exchange has closed a complaint against the company concerning the price of its shares.

Why Is SciSparc (SPRC) Stock Up 105% Today?

NEW YORK, NY / ACCESSWIRE / October 16, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ:SPRC).

Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)

Tel Aviv, Oct. 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), reported the receipt of a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

TEL AVIV, ISRAEL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced the closing of its previously announced private placement with an institutional investor with gross cash proceeds to the company of approximately $5.026 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

SciSparc Ltd. Announces Closing of $5.026 Million Private Placement

TEL AVIV, ISRAEL, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced that it has entered into a securities purchase agreement with an institutional investor to raise gross cash proceeds of approximately $5.026 million through a private placement, before deducting fees to the placement agent and other offering expenses payable by the Company.

SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement

The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space

SciSparc Granted European Patent for its Core Technology

TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, today announced the initiation of a pivotal clinical trial for its drug candidate, SCI-210, at the Soroka University Medical Center. SCI-210 is designed to help control symptoms of Autism Spectrum Disorder (“ASD”) and is an innovative proprietary combination of cannabidiol (“CBD”) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™.

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding

SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

TEL AVIV, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-26. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on September 28, 2023, under the Company's existing trading symbol "SPRC".

SciSparc Announces 1-for-26 Reverse Share Split

TEL AVIV, Israel, Sept. 12, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it has engaged Rosario Capital Ltd. ("Rosario Capital"), one of Israel' leading investment banks, to identify potential opportunities for a strategic transaction.

SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities

Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd.

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd.

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ:SPRC).

Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)

TEL AVIV, Israel, Aug. 14, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately $1.3 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 6,500,000 ordinary shares (or pre-funded warrants in lieu of ordinary shares) at a price to the public of $0.20 per share (or $0.199 per pre-funded warrant). The Company intends to use the net proceeds from this offering primarily for working capital.

SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering

TEL AVIV, ISRAEL, Aug. 10, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.3 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consists of 6,500,000 ordinary shares (or pre-funded warrants in lieu of ordinary shares) at a price to the public of $0.20 per share (less $0.001 in exercise price per pre-funded warrant). The Company intends to use the net proceeds from this offering for working capital.

SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering

TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and dystonia known to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinson's disease.

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

“We hope the outcome of this trial will enable the Company to procced with commercialization process for SCI-210 in Israel" TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder ("ASD").

News for SciSparc Ltd Stock (SPRC)